MiMedx Group

MiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

MiMedx Group reports robust Q4 performance and eyes growth opportunities

MiMedx Group's Q4 2022 earnings call highlighted strong performance, strategic focus on growth objectives, and addressing challenges in reimbursement and regulatory landscape. The company's emphasis on technology, personnel, and growth opportunities positions it for continued success.

MiMedx Group reports robust Q1 performance and eyes international growth

MiMedx Group's Q1 2023 performance reflects a balanced focus on profitability and revenue growth, driven by new product launches and strategic initiatives.
Despite challenges such as product launch delays and market dynamics, the company remains optimistic about growth opportunities in Japan and beyond.
With a strong emphasis on efficiency, innovation, and market expansion, MiMedx Group is positioned for continued growth and success in the evolving healthcare landscape.

MiMedx Group excels in Q2, eyes growth amid challenges

MiMedx Group's Q2 2023 performance reflects strong financial results, operational efficiency, and a strategic shift towards wound and surgical markets.
While facing challenges related to supply chain disruptions and regulatory compliance, the company is well-positioned to capitalize on growth opportunities and drive innovation.
Investors can be optimistic about MiMedx Group's financial outlook, legal standing, and commitment to market expansion through product development and strategic partnerships.

MiMedx Group reports robust Q3 earnings, eyes Japanese market growth

MiMedx Group's Q3 performance reflects strong financial results, strategic product launches, and growth in key markets despite challenges.
The company's focus on operational efficiency, expansion in the Japanese market, and product portfolio diversification position it well for future success.
While facing challenges from Medicare LCD changes and potential cannibalization, MiMedx remains optimistic about growth opportunities and aims for continued momentum.

MiMedx Group excels in Q4, poised for sustained growth

MiMedx Group's Q4 performance exceeded expectations with revenue growth and improved margins.
The company's strategic focus on growth drivers and financial discipline sets a strong foundation for 2024.
While facing challenges in certain areas, MiMedx is well-positioned to capitalize on opportunities for expansion.
Overall, MiMedx's financial health and growth prospects indicate a positive outlook for the future.

MiMedx Group reports robust Q1 earnings amidst strategic growth plans

MiMedx Group (MDXG) had a strong start in Q1 2024, showcasing financial strength and strategic focus on growth.
The company faces challenges from potential market disruptions and cost pressures but remains optimistic about opportunities.
Key initiatives include product innovation, market expansion, and navigating reimbursement landscape changes.

MiMedx Group reports solid Q2 earnings, navigates reimbursement challenges

MiMedx Group's Q2 performance reflects steady growth, strong financial health, and a strategic focus on innovation and customer relationships.
While facing challenges in reimbursement dynamics and regulatory uncertainties, the company remains resilient and poised for growth opportunities in the market.
With a solid product portfolio and emphasis on operational efficiency, MiMedx Group is well-positioned to navigate challenges and capitalize on future market prospects.

MiMedx Group reports solid Q3 growth amid reimbursement challenges

MiMedx Group's Q3 performance reflects resilience and growth amidst challenges, with a focus on innovation and customer-centric strategies for future success.
The company's financial stability, positive market reception of HELIOGEN, and increasing platform adoption position it well for capitalizing on opportunities ahead.
While facing challenges in reimbursement dynamics and operational efficiency, MiMedx Group remains optimistic about future corrections and growth prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BATON ROUGE, La., May 4, 2021 /PRNewswire/ -- Prescience Point Capital Management ("Prescience Point"), a research-focused, catalyst-driven investment firm that is the beneficial owner of approximately 8.1% of the outstanding shares of MiMedx Group, Inc. (NASDAQ: MDXG) ("MiMedx" or the "Company"), today announced that it has withdrawn its slate of nominees for election to the Board of Directors at the Annual Meeting of Shareholders (the "Annual Meeting"), scheduled to be held on May 27, 2021.

Prescience Point Announces Withdrawal of Its Slate of Nominees to MiMedx's Board

Questions Every Shareholder Should Ask Prescience Point

MIMEDX Urges Shareholders to Consider Prescience Point's Motivations Before Voting Their Shares at the Company's Annual Meeting

Urges Shareholders to Vote the WHITE Proxy Card “FOR ALL” Four of MIMEDX's Director Nominees – Dr. Kathleen Behrens, Mr. Todd Newton, Mr. Timothy Wright, and Dr. Phyllis Gardner

MIMEDX Files Definitive Proxy Materials and Mails Letter to Shareholders Highlighting Actions Taken to Transform MIMEDX and Drive Significant Value for Shareholders

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q1 2021 Results - Earnings Call Transcript

MiMedx Announces First Quarter 2021 Financial and Operating Results

Accomplished Regulatory Leader Joins MiMedx Management Team

MiMedx Welcomes Dirk Stevens, Ph.D., as Senior Vice President, Quality Assurance and Regulatory Affairs

MARIETTA, Ga., April 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report financial results for the first quarter ended March 31, 2021 after the market close on Wednesday, April 28, 2021. MiMedx management will host a webcast and conference call to review its results on Thursday, April 29, 2021, beginning at 8:30 am Eastern Time. Participating on the call will be Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer.

MiMedx to Host First Quarter 2021 Operating and Financial Results Conference Call on April 29

Advances Potential for Use of Micronized Dehydrated Human Amnion Chorion Membrane (mdHACM) as a Safe and Effective Treatment Option

MiMedx Announces Last Patients Last Visits in Three Late-Stage Musculoskeletal Trials with Proprietary Tissue Technology

No Shareholder Action Required at This Time

MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management

BATON ROUGE, La., April 16, 2021 /PRNewswire/ -- Prescience Point Capital Management, together with its affiliates ("Prescience Point"), a research-focused, catalyst-driven investment firm, announced today the nomination of four highly qualified director candidates to the Board of Directors (the "Board") of MiMedx Group, Inc. (NASDAQ: MDXG) ("MiMedx" or the "Company").

Prescience Point Capital Management to Nominate Four Highly Qualified Director Candidates to MiMedx Board at 2021 Annual Meeting

The stock price of MiMedx Group, Inc. (Nasdaq: MDXG) has increased by over 5% pre-market. This is why it happened.

MDXG Stock Price Increased Over 5% Pre-Market: Why It Happened

MARIETTA, Ga., March 30, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today announced that the Company has been awarded a Group Purchasing Agreement for its amniotic tissue portfolio with Premier Inc.'s Synergizing for Unparalleled Results in Procurement and Strategic Sourcing (SURPASS) purchasing program. Effective April 1, 2021, the new Regenerative Skin Grafting Products agreement allows SURPASS members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the MiMedx's placental-based tissue advanced wound care products.

MiMedx Awarded Amniotic Tissue Supplier Agreement with Premier® Inc.'s SURPASS™ Purchasing Program

The stock price of MiMedx Group Inc (NASDAQ: MDXG) has increased by 15.21%. This is why it happened.

MDXG Stock Price Increased 15.21%: Why It Happened

FDA scare for $20M-25M a year does not change the long-term profit narrative for MiMedx.

MiMedx: Aggressively Adding Shares Here

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q4 2020 Results - Earnings Call Transcript

Noted biopharmaceutical thought leader adds academic, research and industry expertise

MiMedx Announces Appointment of Phyllis Gardner, M.D. to Board of Directors

Fourth Quarter Net Sales of $68.5 million, Full Year 2020 Net Sales of $248.2 million

MiMedx Announces Fourth Quarter and Full Year 2020 Financial and Operating Results

MARIETTA, Ga., March 02, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2020 after the market close on Monday, March 8, 2021. MiMedx management will host a webcast and conference call to review its results on Tuesday, March 9, 2021, beginning at 9:30 am, Eastern Time. Participating on the call will be Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development.

MiMedx to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call on March 9

MARIETTA, Ga., Feb. 10, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021 at 3:30 PM Eastern Time.

MiMedx to Participate at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Persistent and sustained institutional buying in MiMedx should not be ignored as heavy hitters position themselves for key knee osteoarthritis data in 2021. Sales and revenue growth after two years of floundering could cause additional explosive upside.

MiMedx: This Is What Institutional Investment Looks Like

Significant evidence indicates that Amniofix is a highly effective and safe treatment for knee OA, and that the product will likely receive FDA approval for this indication. The RMAT designation further increases Amniofix's chances of being approved, and gives MDXG the opportunity to apply for early approval after the Phase 2b knee OA trial is completed.

MiMedx: Raising Our PT To $31 On New Findings That Indicate Amniofix Will Be A Blockbuster, Game-Changing Osteoarthritis Treatment

Experienced Healthcare Executive Will Expand Company's Visibility Within the Financial Community

MiMedx Appoints Jack Howarth as Senior Vice President, Investor Relations

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020.

MiMedx To Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

MiMedx Group is in the early stages of a sales recovery, after a turbulent last 2 years. 90% of management are new faces, and the new growth strategy dovetails to include commercialization, R&D focus and supply chain integration.

MiMedx: Amniotic Hypotheses Create Decent Fundamental Momentum

MARIETTA, Ga., Nov. 13, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today provided additional information about its upcoming virtual 2020 Annual Meeting of Shareholders (“Annual Meeting”). Timothy R. Wright, Chief Executive Officer, is scheduled to present an overview of the Company, and Rohit Kashyap, Ph.D., Executive Vice President and Chief Commercial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, are scheduled to present an overview of the Company's commercial and R&D initiatives. Additional members of senior management also plan to be available for a question and answer session from shareholders as of the record date of 5:00 p.m. Eastern Time on October 7, 2020. Guests may join the virtual 2020 Annual Meeting, including the shareholder question and answer session, in a listen-only mode without a control number.

News for MiMedx Group Stock (MDXG)